• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

U.S. Genomics(TM) Introduces the Direct(TM) Results Direct miRNA Service Program

Posted on: Tuesday, 9 August 2005, 09:00 CDT

U.S. Genomics(TM), a pioneer of single molecule biology tools for life sciences, unveiled its Direct(TM) Results fee-for-service program today. The new service enables researchers to use single molecule technology to accurately quantitate the microRNAs (miRNAs) in their samples. By quantitating single molecules, rather than amplifying a large population of molecules, scientists can perform genetic, functional genomic and diagnostic research at the molecular level with unparalleled accuracy.

The new Direct(TM) Results fee-for-service program uses U.S. Genomics' Trilogy(TM) 2020 Single Molecule Analyzer to enable scientists to detect individual molecules of miRNA with U.S. Genomics' Direct(TM) miRNA assays. Launched in March of 2005, the Trilogy(TM) 2020 is the first commercial technology to directly detect and quantitate individual molecules without amplification. Using this service, scientists interested in obtaining direct, accurate measurements of the levels of specific miRNAs in their RNA samples will now be able to submit these samples to U.S. Genomics for quantitative analysis in several species, including human, mouse, rat, and chicken.

"The launch of the Direct(TM) Results Program demonstrates our commitment to providing researchers with important technology now," said John Canepa, Acting CEO and CFO of U.S. Genomics. "Until recently, this level of accuracy was well beyond the capability of the average biologist in terms of technology. The Direct(TM) Results service program opens the field and methods of single molecule biology to small RNA researchers, and adds cutting-edge techniques to their experimental arsenal. The accuracy and convenience is here for them now."

Conventional technologies to characterize RNA and other molecules study millions of molecules at a time and rely on amplification and measurement of bulk fluorescence. These methods are known to create inherent errors and can undermine a researcher's ability to achieve accurate, quantitative results. The Trilogy(TM) 2020 Single Molecule Analyzer uniquely combines advances in microfluidics, optical engineering, and labeling strategies to eliminate the bias of amplification. As a result, researchers can now accurately examine how cellular elements function and interact within biological pathways.

U.S. Genomics will give a product demonstration of the Trilogy(TM) 2020 Single Molecule Analyzer at the Drug Discovery Technology Conference in Boston on August 10, at 1:00 P.M. on the Keynote Stage of the Exhibit Hall at the Boston Convention and Exhibition Center. Jenny Rooke Ph.D, Vice President of Research and Development at U.S. Genomics, will present the Trilogy(TM) 2020 and the Direct(TM) miRNA assays.

About U.S. Genomics

U.S. Genomics is pioneering single molecule biology tools for the life sciences industry. The Company provides instruments and reagents for researchers in academia, pharmaceutical and biotechnology companies, and contract service organizations. Combining advances in microfluidics, optical engineering, and novel labeling strategies, U.S. Genomics' innovative technologies allow applications in genetics, functional genomics, biodefense, and diagnostics to be performed at the single molecule level. The Trilogy(TM) platform is the first commercial technology to enable the direct detection and analysis of individual molecules of DNA, RNA, and proteins without the need for amplification. In addition, the Company is developing the next generation of biodetection technology for the U.S. Department of Homeland Security. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease pathways, and ultimately lead to more effective therapeutics and diagnostics. For more information, please visit www.usgenomics.com.

Trilogy, Direct (as in Direct miRNA), and U.S. Genomics are trademarks of U.S. Genomics, Inc.

Source: Business Wire

More News in this Category